The gist of it
CorMedix spent years burning cash with no product revenue at all. Then, in a single fiscal year, it turned profitable, with the 10-K for FY2025 showing a 52% net margin on $312 million in revenue. The stock is down 28% over the past twelve months. One interpretation of that price level is that the market assigns a high probability that the profitability is temporary or already reflected; another is that the market is discounting risks not visible in the current filings. Both readings are live. An 8-K filed October 19, 2026 just added a new variable: the FDA accepted a second drug for Priority Review, with a decision due in early 2027. The math says profitable and growing; the mood says skeptical. That gap is the analytical question the filings raise but do not resolve.
From nothing to $312 million in one leap
For most of its life, CorMedix was a company with a drug but no sales. The 10-K for FY2023 shows essentially zero revenue and a net loss so deep the margin figure runs to five digits. That is what years of clinical-stage spending looks like on a spreadsheet: a company paying for science before science pays back.
The turn came with DefenCath, a catheter-lock solution that prevents bloodstream infections in dialysis patients, a population that visits a clinic three times a week and faces infection as a routine mortal risk. DefenCath’s commercial launch, combined with the acquisition of the Melinta antibiotic portfolio, pushed FY2025 revenue to $312 million and flipped the bottom line to a 52% net margin, meaning more than half of every dollar of sales became profit. That is not a small company finding its footing. That is a structural change.
The most recent quarterly filing, the 10-Q for Q2 2026 ended June 30, shows the momentum holding: consolidated revenue for a single quarter split between DefenCath and the Melinta portfolio, with net income of $26 million. A company that reported no revenue three years ago is now generating more than a hundred million dollars in a single quarter. For anyone mapping the company’s trajectory from the public record, that revenue arc is the central quantitative fact.
What the October 8-K actually changes
Priority Review is the FDA’s way of saying a drug addresses a serious condition and, if approved, would represent a meaningful improvement over existing options. It shortens the standard review clock by several months, which matters because time is money in drug development. The 8-K filed October 19 reports that the FDA accepted CorMedix’s supplemental application for REZZAYO, a drug already approved for treating certain fungal infections, now seeking approval for preventing them in patients at high risk. The PDUFA date, the FDA’s self-imposed decision deadline, falls in the first quarter of 2027.
Prophylaxis, meaning prevention rather than treatment, is a larger commercial opportunity than treatment alone. A drug given to every high-risk patient before an infection occurs reaches far more people than one reserved for those already sick. If the FDA approves the expanded label, REZZAYO moves from a rescue drug to a routine one. That is a meaningful commercial distinction, and it sits entirely in the future, unconfirmed.
The number the stock ignores
The math and the mood, as we use those terms, are the tension between what filed fundamentals show and what the market currently pays. The math here is striking: our data shows CorMedix trading at roughly 3.9 times earnings, against a price-to-sales ratio of 2.0. A company with a strong net margin, a cash position well above a quarter-billion dollars at June 30, and a potential second commercial catalyst trades at a P/E of roughly 3.9. Whether that multiple reflects rational discounting of durability risk or a lag in market recognition is a question the current public record does not answer definitively.
That skepticism is not irrational. The Melinta portfolio was acquired, not built, and acquired revenue can be lumpy or contract-dependent in ways that organic growth is not. The dossier does not detail the specific terms of those agreements, so we cannot assess their durability from here. That is a genuine limit of what the public record tells us.
What the filing cannot tell us
The 8-K is a single event notice, not a full financial update. It confirms FDA acceptance and a review timeline. It does not tell us how large the prophylaxis market is, what pricing looks like, or whether the Melinta portfolio revenue is stable or declining. The Q2 2026 10-Q is the most recent financial window, and it is now four months old. A Q3 2026 filing would update the picture, but none has appeared in the dossier as of today.
The open question is whether the profitability that appeared in FY2025 is structural or situational. A company that went from zero revenue to hundreds of millions in one year, partly through acquisition, has not yet proven that the new shape holds. The FDA decision in early 2027 will either add a second growth engine or leave the current one to carry the full weight.
Reading the numbers
- $312 million FY2025 revenue, 52% net margin (10-K FY2025). Revenue is what the company collected from customers. A 52% net margin means that after every cost, including manufacturing, sales, and administration, 52 cents of each dollar stayed as profit. A household analogy: if a family earned $100,000 and kept $52,000 after all bills, that would be an unusually efficient operation. For a pharmaceutical company that had no revenue three years prior, it signals that the product economics are strong, not just that sales exist.
- $101.9 million Q2 2026 revenue, $26 million net income (10-Q Q2 2026). At this quarterly run rate, the company is on pace for roughly $400 million annualized, ahead of FY2025. The $26 million net income for a single quarter means the business is generating real cash, not just accounting profit. That matters because cash funds the next drug’s development without requiring new investors to dilute existing ones.
- $256.7 million cash at June 30, 2026 (10-Q Q2 2026). Cash on hand is the company’s buffer against setbacks. At $256.7 million, and with the business generating positive income, CorMedix is not in the position of needing to raise money urgently. A company that must sell new shares to survive dilutes the value of existing ones; this company, at present, does not appear to face that pressure.
- P/E of 3.9, stock down 37% from 52-week high (our data). A price-to-earnings multiple, or P/E, is the price tag the market puts on each dollar of annual profit. At 3.9, the market is paying less than $4 for every $1 of annual earnings. Whether that multiple is low relative to peers or reflects specific risks, such as acquired-revenue durability or pipeline uncertainty, depends on comparisons the current dossier does not fully support. The 37% decline from the 52-week high, occurring alongside rising reported profits, is one quantitative way to describe the divergence between filed fundamentals and current price; the filings do not explain whether that divergence reflects unresolved risk or delayed recognition.
Sources
- CorMedix 8-K filed October 19, 2026 (SEC EDGAR)
- CorMedix 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- CorMedix 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- CorMedix 10-K for fiscal year ended December 31, 2023 (SEC EDGAR)
- CorMedix SEC filings index (MarketBeat)
